| Jul 21 | Apr 20 | |
|---|---|---|
| Income Statement | ||
| Total Revenue | C$ 276.47K | C$ 0.00 |
| Gross Profit | C$ 89.69K | C$ 0.00 |
| Operating Income | C$ -9.81M | C$ -40.58K |
| EBITDA | C$ -21.80M | C$ -40.58K |
| Net Income | C$ -22.44M | C$ -40.58K |
| Balance Sheet | ||
| Cash & Short-Term Investments | C$ 1.06M | C$ 1.62M |
| Total Assets | C$ 4.06M | C$ 1.94M |
| Total Debt | C$ 389.35K | C$ 0.00 |
| Net Debt | C$ -666.30K | C$ -1.62M |
| Total Liabilities | C$ 918.46K | C$ 41.11K |
| Stockholders' Equity | C$ 3.14M | C$ 1.90M |
| Cash Flow | ||
| Free Cash Flow | C$ -7.98M | C$ -75.02K |
| Operating Cash Flow | C$ -7.88M | C$ -75.02K |
| Investing Cash Flow | C$ -2.03M | C$ -250.00K |
| Financing Cash Flow | C$ 1.56M | C$ 1.94M |
HAVN Life Sciences (DE:5NP0)
FRANKFURT:5NP0
